Q3 2024 EPS Estimates for Acadia Healthcare Company, Inc. Lowered by Zacks Research (NASDAQ:ACHC)

Acadia Healthcare Company, Inc. (NASDAQ:ACHC) – Analysts at Zacks Research reduced their Q3 2024 earnings per share (EPS) estimates for shares of Acadia Healthcare in a report released on Wednesday, August 14th. Zacks Research analyst Z. Masood now anticipates that the company will post earnings per share of $0.90 for the quarter, down from their previous forecast of $0.93. The consensus estimate for Acadia Healthcare’s current full-year earnings is $3.51 per share. Zacks Research also issued estimates for Acadia Healthcare’s Q1 2025 earnings at $0.85 EPS, FY2025 earnings at $3.85 EPS, Q2 2026 earnings at $1.14 EPS and FY2026 earnings at $4.38 EPS.

Acadia Healthcare (NASDAQ:ACHC) last posted its quarterly earnings data on Wednesday, July 31st. The company reported $0.91 earnings per share for the quarter, topping the consensus estimate of $0.87 by $0.04. Acadia Healthcare had a negative net margin of 0.17% and a positive return on equity of 11.42%. The company had revenue of $796.00 million for the quarter, compared to analysts’ expectations of $784.38 million. During the same period in the prior year, the business earned $0.92 earnings per share. Acadia Healthcare’s revenue for the quarter was up 8.8% compared to the same quarter last year.

Other equities research analysts also recently issued research reports about the company. StockNews.com downgraded Acadia Healthcare from a “hold” rating to a “sell” rating in a research report on Tuesday, May 21st. TD Cowen decreased their price objective on Acadia Healthcare from $101.00 to $91.00 and set a “buy” rating on the stock in a report on Friday, May 17th. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $90.00 target price on shares of Acadia Healthcare in a research note on Thursday, August 1st. Royal Bank of Canada reissued an “outperform” rating and set a $94.00 price target on shares of Acadia Healthcare in a research note on Wednesday, May 22nd. Finally, Deutsche Bank Aktiengesellschaft upped their price objective on shares of Acadia Healthcare from $70.00 to $75.00 and gave the company a “hold” rating in a research note on Friday, August 2nd. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, Acadia Healthcare has a consensus rating of “Moderate Buy” and an average price target of $87.44.

Acadia Healthcare Stock Performance

Acadia Healthcare stock opened at $74.47 on Friday. Acadia Healthcare has a fifty-two week low of $62.04 and a fifty-two week high of $87.77. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.27 and a current ratio of 1.18. The stock has a market cap of $6.91 billion, a P/E ratio of -531.93, a price-to-earnings-growth ratio of 2.21 and a beta of 1.32. The firm’s fifty day moving average price is $68.08 and its 200-day moving average price is $72.91.

Institutional Trading of Acadia Healthcare

A number of institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. raised its holdings in Acadia Healthcare by 0.3% during the 4th quarter. Vanguard Group Inc. now owns 8,861,427 shares of the company’s stock valued at $689,065,000 after buying an additional 30,296 shares during the last quarter. William Blair Investment Management LLC increased its position in shares of Acadia Healthcare by 20.7% in the second quarter. William Blair Investment Management LLC now owns 3,515,464 shares of the company’s stock valued at $237,434,000 after acquiring an additional 604,070 shares during the period. Point72 Asset Management L.P. raised its stake in shares of Acadia Healthcare by 266.0% during the second quarter. Point72 Asset Management L.P. now owns 2,270,340 shares of the company’s stock valued at $153,339,000 after acquiring an additional 1,650,040 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Acadia Healthcare by 6.6% during the second quarter. Bank of New York Mellon Corp now owns 1,249,369 shares of the company’s stock worth $84,382,000 after purchasing an additional 77,509 shares during the period. Finally, Avidity Partners Management LP grew its stake in shares of Acadia Healthcare by 61.8% in the fourth quarter. Avidity Partners Management LP now owns 1,156,692 shares of the company’s stock worth $89,944,000 after purchasing an additional 441,692 shares during the last quarter.

About Acadia Healthcare

Acadia Healthcare Company, Inc provides behavioral healthcare services in the United States and Puerto Rico. The company develops and operates acute inpatient psychiatric facilities, specialty treatment facilities comprising residential recovery facilities and eating disorder facilities, comprehensive treatment centers, and residential treatment centers, as well as facilities offering outpatient behavioral healthcare services for the behavioral healthcare and recovery needs of communities.